Cargando…
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma
Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding...
Autores principales: | Zustovich, Fable, Lombardi, Giuseppe, Pastorelli, Davide, Farina, Patrizia, Bianco, Massimo Dal, De Zorzi, Luca, Palma, Maurizia Dalla, Nicoletto, Ornella, Zagonel, Vittorina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818940/ https://www.ncbi.nlm.nih.gov/pubmed/24198638 http://dx.doi.org/10.2147/OAJU.S7230 |
Ejemplares similares
-
The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014) -
Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature
por: Farina, Patrizia, et al.
Publicado: (2014) -
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022) -
Targeted α Therapies for the Treatment of Bone Metastases
por: Zustovich, Fable, et al.
Publicado: (2017) -
An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)